{"id":"W4387673858","doi":"10.1038/s41591-023-02639-3","title":"Author Correction: Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial","year":2023,"lang":"en","type":"erratum","venue":"Nature Medicine","topic":"Cholinesterase and Neurodegenerative Diseases","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Douglas Mental Health University Institute","funders":"NIHR Sheffield Biomedical Research Centre; NIHR Sheffield Clinical Research Facility; Sheffield Teaching Hospitals NHS Foundation Trust; National Institute for Health and Care Research","keywords":"Placebo; Oligonucleotide; Randomized controlled trial; Medicine; Disease; Alzheimer's disease; Internal medicine; Pharmacology; Oncology; Biology; Pathology; Genetics; Gene; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009218176,0.001820856,0.00271229,0.001153254,0.001182612,0.002212762,0.002175712,0.005105921,0.04245567],"category_scores_gemma":[0.06254029,0.0006917313,0.002290225,0.001286104,0.0011369,0.001026671,0.0006501721,0.006944111,0.01100253],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003223144,"about_ca_system_score_gemma":0.004848584,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.008824946,"about_ca_topic_score_gemma":0.0144205,"domain_scores_codex":[0.9961773,0.001194875,0.0007680763,0.0004926586,0.001164092,0.0002029064],"domain_scores_gemma":[0.9796056,0.01034769,0.001388054,0.0007779038,0.006997253,0.0008835092],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.000842968,0.00001456429,0.00007068292,0.0009898472,0.0001586981,0.0002556374,0.0000160718,0.00004470062,0.00006999656,0.0004334552,0.989906,0.007197468],"study_design_scores_gemma":[0.0161067,0.000544579,0.003049928,0.006874122,0.002818134,0.001754924,0.0001166083,0.0009735855,0.001551655,0.003388712,0.9626418,0.000179272],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"editorial","genre_gemma":"other","genre_scores_codex":[0.0005565486,0.006369629,0.000962762,0.07618967,0.9086136,0.0003278954,0.003189369,0.0003089861,0.003481532],"genre_scores_gemma":[0.04415653,0.02590021,0.01111392,0.3491868,0.3390092,0.002642866,0.00545299,0.00162517,0.2209123],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.04245567,"threshold_uncertainty_score":0.1420284,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03258807000233051,"score_gpt":0.366856058647932,"score_spread":0.3342679886456015,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}